Sunday, January 11, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Karyopharms Revenue Projections for 2024

Elaine Mendonca by Elaine Mendonca
February 29, 2024
in Breaking News
0
0
SHARES
7
VIEWS
Share on FacebookShare on Twitter

Karyopharm anticipates generating total revenue between $140 million and $160 million in 2024, with projections slightly below the estimated figure of $152.02 million.

Karyopharm Therapeutics Inc. (KPTI) Shows Promising Stock Performance on February 29, 2024

On February 29, 2024, Karyopharm Therapeutics Inc. (KPTI) showed promising stock performance, trading near the bottom of its 52-week range but above its 200-day simple moving average. This indicates that the stock may be in a position to potentially rebound and move higher in the near future.

The price of KPTI shares increased by $0.10 since the market last closed, representing a significant 7.63% rise. This positive price momentum suggests that investors have shown renewed interest in the stock, possibly due to positive news or developments related to the company.

Closing at $1.41, KPTI stock continued to show strength in after-hours trading, rising by $0.03. This further demonstrates the bullish sentiment surrounding the stock and indicates that investors are confident in its potential for future growth.

Investors may want to keep a close eye on KPTI in the coming days to see if this positive momentum continues. While past performance is not indicative of future results, the recent price movements suggest that KPTI may have the potential for further upside in the short term.

Consulting with a financial advisor can provide valuable insights and guidance on how to best navigate the stock market.

KPTI Stock Declines in Financial Performance: A Closer Look at Revenue, Net Income, and EPS

On February 29, 2024, KPTI stock experienced a decline in its financial performance compared to the previous year and the previous quarter. According to data from CNN Money, the total revenue for KPTI was $157.07 million over the past year, which decreased by 25.14% compared to the previous year. In the third quarter of the fiscal year, the total revenue was $36.01 million, showing a decrease of 4.18% compared to the previous quarter.

The net income for KPTI was reported as -$165.29 million over the past year, indicating a decrease of 33.2% compared to the previous year. In the third quarter, the net income was -$34.51 million, showing a decrease of 5.75% compared to the previous quarter.

The earnings per share (EPS) for KPTI were reported as -$2.02 over the past year, which decreased by 22.38% compared to the previous year. In the third quarter, the EPS was reported as -$0.30, showing a decrease of 5.57% compared to the previous quarter.

These financial metrics indicate a downward trend in KPTI’s performance, which may have contributed to the stock’s performance on February 29, 2024. Investors and analysts may be closely monitoring the company’s financial health and future prospects to determine the potential impact on the stock price. It is essential for investors to conduct thorough research and analysis before making investment decisions.

Tags: KPTI
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post

Verrica Pharmaceuticals Reports Strong Q4 Financial Results and Growth Plans

Healthcare-and-IT

Inari Medical Receives Buy Recommendation with Adjusted Price Target

Agrify Corporation Announces Major Sales Agreement with HarvestWorks Farm

Recommended

BioNTech Stock

BioNTech Shares Surge on Upbeat Revenue Outlook

2 months ago
Biotechnology Markets and money

Analyst Maintains Positive Outlook on 10x Genomics with Adjusted Price Target

2 years ago
Assembly Biosciences Stock

Analyst Divide Emerges as Assembly Biosciences Shares Swing

3 months ago
BAE Systems Stock

Defense Giant BAE Systems Accelerates on Major Contracts and Strategic Moves

4 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Freshworks Shares Gain on Strategic Pricing and Acquisition Moves

A Domestic Focus Fuels Record Rally for Metals and Mining ETF

Sana Biotechnology Shares Gain on Analyst Upgrade and Upcoming Catalyst

Silver Nears Historic Peak Amid Rate Cut Speculation and Supply Concerns

IBM’s Strategic Pivot Gains Favor with Market Analysts

BioNTech Shares Show Resilience Amidst Legal Challenge

Trending

BYD Stock
Analysis

BYD Surpasses Tesla to Claim Global EV Sales Crown

by Felix Baarz
January 11, 2026
0

The electric vehicle landscape has a new leader. In 2025, BYD definitively overtook Tesla to become the...

SpaceX Stock

A Trio of Catalysts Propels SpaceX Forward

January 10, 2026
21Vianet Stock

Assessing 21Vianet’s Impressive Yet Uncertain Stock Surge

January 10, 2026
Freshworks Stock

Freshworks Shares Gain on Strategic Pricing and Acquisition Moves

January 10, 2026
SPDR® S&P Metals and Mining ETF Stock

A Domestic Focus Fuels Record Rally for Metals and Mining ETF

January 10, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • BYD Surpasses Tesla to Claim Global EV Sales Crown
  • A Trio of Catalysts Propels SpaceX Forward
  • Assessing 21Vianet’s Impressive Yet Uncertain Stock Surge

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com